Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM, Masala G, Antonioli E, Chiara Susini M, Guglielmelli P, Pieri L, Maggi L, Caini S, Palli D, Bogani C, Ponziani V, Pancrazzi A, Annunziato F, Bosi A. Vannucchi AM, et al. Among authors: pieri l. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2068-73. doi: 10.1158/1055-9965.EPI-09-0353. Epub 2009 Jun 16. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19531676
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC). Antonioli E, et al. Among authors: pieri l. Haematologica. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653. Haematologica. 2008. PMID: 18166784 Free article.
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM. Guglielmelli P, et al. Among authors: pieri l. Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23. Blood. 2009. PMID: 19549988 Free article.
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, Magrini U, Massa M, Tinelli C, Viarengo G, Villani L, Primignani M, Vannucchi AM, Frassoni F, Barosi G; AGIMM Investigators. Rosti V, et al. PLoS One. 2010 Dec 9;5(12):e15277. doi: 10.1371/journal.pone.0015277. PLoS One. 2010. PMID: 21151606 Free PMC article.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Guglielmelli P, et al. Among authors: pieri l. Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1. Blood. 2011. PMID: 21725052 Free PMC article. Clinical Trial.
Risk of second cancers in chronic myeloproliferative neoplasms.
Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, Bosi A, Vannucchi AM. Susini MC, et al. Among authors: pieri l. Blood. 2012 Apr 19;119(16):3861-2; author reply 3862-3. doi: 10.1182/blood-2011-12-401455. Blood. 2012. PMID: 22517876 Free article. No abstract available.
260 results